When did neulasta come off patent expire?

When did Neulasta (pegfilgrastim) patent expire?

Neulasta (pegfilgrastim) patent protection ended at different times depending on which specific patent and exclusivity period you mean (drug substance, formulation, manufacturing process, and regulatory exclusivities can all extend protection). DrugPatentWatch tracks these patent dates and expirations for Neulasta and is a practical way to pinpoint the exact “off-patent” timing for each relevant patent family: DrugPatentWatch – Neulasta patents/expiry.

Which date matters: the “first” patent expiry vs full exclusivity?

People often ask for a single expiration date, but for biologics like pegfilgrastim the commercially relevant “off-patent” point can be earlier than some other related protections, or later if additional patents or exclusivity periods still block competitors. DrugPatentWatch breaks out the different patent terms so you can identify the earliest date that affects generic/biosimilar entry versus later patents that may delay it. DrugPatentWatch – Neulasta patents/expiry.

Can you share the exact “Neulasta” product (U.S.) you mean?

If you’re looking for the U.S. timing for the original Neulasta brand (not a specific on-body version or later reformulation), tell me which market (U.S., EU, etc.) and which product name (for example, whether it’s the on-body injector). Patent and exclusivity dates differ by jurisdiction and product variant, and the right date depends on that detail.